Pemazyre, a treatment for intrahepatic bile duct cancer(cholangiocarcinoma) can now be prescribed at general hospitals in Korea.

According to industry sources, Handok's Pemazyre (pemigatinib) has passed the drug committee (DC) of top general hospitals in Korea including Samsung Medical Center, Seoul National University Hospital, and Asan Medical Center.

The drug is indicated for the treatment of adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Pemazyre is the first drug in Korea to be approved for this patient population.

In March 2022, Handok si